miRagen Therapeutics Announces Proposed Public Offering of Common Stock

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced that it intends to offer for sale 7,000,000 shares of its common stock in an underwritten public offering.

As quoted in the press release:

miRagen intends to use the net proceeds from this offering for working capital and general corporate purposes, which include the funding of clinical development of its product candidates, and general and administrative expenses.

Click here to read the full press release.